Tensions between Japan and South Korea come as the U.S. and its trading partners are embroiled in a global trade war.Technologyread more
The one-to-eight stock split would mean the current number of ordinary shares — which stands at 4 billion — will increase to 32 billion. It comes ahead of a reported Hong Kong...Asia Marketsread more
Minutes from the Reserve Bank of Australia's monetary policy meeting in July showed the central bank was ready to adjust interest rates if required.Asia Marketsread more
Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
China's fiscal spending increased 10.7% in the first six months from a year earlier, the finance ministry said on Tuesday, underlining the government's bid to support the...China Economyread more
The findings by McKinsey and Company come amid a year-long tariff fight between the U.S. and China, which has spilled into areas such as technology and security.China Economyread more
Microsoft's considerable reach into the corporate world isn't something Slack CEO Stewart Butterfield is very concerned about.Technologyread more
Von der Leyen, one of the longest serving ministers in Germany, has tried to woo European lawmakers over the last two weeks.Europe Newsread more
A devastating outbreak of African swine fever that has killed millions of pigs in China is changing attitudes in a country where farm hygiene has often been seen as lax by...Livestockread more
In a closed-door meeting at a Manhattan mansion, executives outlined changes to controversial software that was implicated in two crashes.Aerospace & Defenseread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
Pfizer's talks to acquire Allergan in a $150 billion deal that would see the U.S. drug giant redomicile in Ireland accelerated on Wednesday, as the U.S. Treasury prepared to clamp down further on such tax inversions.
Pfizer is negotiating a price of $370 to $380 for each Allergan share, a person familiar with the discussions said, asking not to be identified because the talks are confidential. Allergan shares ended trading on Wednesday at $310.8 per share.
While negotiations have made progress in recent days, an agreement is not imminent and its timing remains uncertain following the Treasury's disclosure that it would seek to tighten the rules on inversions, the source added.
Inversions typically involve a U.S. multinational buying a smaller foreign competitor and relocating to its home country, if only on paper, to escape U.S. taxation. Ireland is a common destination. Management usually stays in the United States.
"Later this week, we intend to issue additional targeted guidance to deter and reduce further the economic benefits of corporate inversions," according to a letter from the Treasury seen by Reuters.
Pfizer was not named in the letter, which was signed by Treasury Secretary Jack Lew and addressed to four senior lawmakers: U.S. Senators Ron Wyden and Orrin Hatch, and Representatives Kevin Brady and Sander Levin. All four serve on the Senate and House tax committees.
"We have no further comment beyond what is in the letter, at this time," a Treasury spokesman said. Pfizer and Allergan also declined to comment.
Levin said in a statement: "The fact that American companies, including Pfizer, continue to pursue inversions makes clear that additional steps are needed to stop this trend."
Noting that Treasury can only do so much on its own, Levin urged Congress to "get off the sidelines and take action to change the law to stop these tax-motivated inversions."
As a wave of inversions peaked in September 2014, Treasury took several regulatory actions to reduce the tax benefits of inverting, while also making new deals more difficult. That slowed deal flow but did not stop it entirely.
For months tax experts have speculated about what could come next from Treasury. Possible steps might include tightening the rules on two strategies related to inversions, tax experts said: so-called "earnings stripping" and "skinny down" distributions.
Earnings-stripping rules combat shifting of U.S. profits out of the country to low-tax jurisdictions. Treasury has struggled to write new rules on this under present law, said tax experts.
Rules targeting skinny-down distributions are meant to keep U.S. companies from shrinking their operations ahead of inversions to evade standards for minimum levels of foreign ownership in inverted companies.
A combination of Dublin-based Allergan with New York-based Pfizer would follow an unprecedented wave of consolidation in the pharmaceutical industry as companies seek access to new drugs and increased leverage on pricing.
Apart from tax considerations, a deal would give Pfizer access to Allergan's dominance in the aesthetics and ophthalmology markets, and displace Johnson & Johnson as the world's biggest healthcare group.
Bloomberg News first reported on the price that Pfizer and Allergan were discussing.